Research
Cellular
Microneedle (MN)-based technologies provide a painless drug delivery approach that targets adipose tissue directly, minimizing systemic exposure and reducing the required dosage.
Practitioners may consider MNs as a viable alternative for delivering anti-obesity medications effectively.
StrongSupportsmedium confidence
transdermal administration of drugs with microneedle (MN)-based technologies, a painless drug delivery approach with patient compliance, is gaining interest as an alternative obesity treatment, as it directly targets adipose tissue via local delivery, minimizing system exposure and dose reduction.
Why this rating
The abstract discusses a review of current strategies and technologies.
Source
Role of Microneedles for Improved Treatment of Obesity: Progress and Challenges
Sudarshan Naidu Chilamakuri et al. · Molecular Pharmaceutics · 2025
DOI 10.1021/acs.molpharmaceut.4c01115
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →